Mankind Pharma
Mankind Pharma, established in 1995, has solidified its status as one of India’s leading pharmaceutical companies, marked by substantial domestic sales and a commitment to a diverse healthcare portfolio.
Their comprehensive approach encompasses the entire pharmaceutical life cycle, including development, manufacturing, and marketing, offering an extensive range of formulations tailored for both acute and chronic therapeutic needs. Beyond pharmaceuticals, Mankind Pharma extends its influence into the consumer healthcare space with a varied product lineup.
API’s of Mankind Pharma
In the domain of Active Pharmaceutical Ingredients (APIs), Mankind Pharma employs a versatile manufacturing strategy, utilizing processes like nitration, Grignard reactions, halogenation, Friedel-Crafts acylation, oxidation, and reduction. This approach allows them to diversify their product range, covering everything from initial laboratory-scale research to full-scale commercial production.
Their team of scientists is recognized for their expertise in intricate areas such as chiral chemistry, polymer-based chemistry, and peptides chemistry. This proficiency extends to the synthesis of complex pharmaceutical products, encompassing therapeutic categories like antihypertensive, antibiotic, antipsychotic, antacid, antianginal, and antithrombotic medications. Mankind’s commitment to innovation positions them as a significant contributor to healthcare advancements across various domains.
- Atorvastatin Calcium
- Baclofen
- Brivaracetam
- Clomipramine HCI
- Clozapine
- Cilnidipine
- Dydrogesterone
- Etoricoxib
- Haloperidol Base
- Haloperidol Decanoate
- Lasmiditan Hemisuccinate
- Lifltegrast
- Luliconazole
- Nitrofurantoin Macrocrystals
- Nitrofurantoin Monohydrate
- Obeticholic Acid
- Pantoprazole Sodium Sesquihydrate
- Propranolol HCI
- Ranolazine
- Revefenacin
- Rosuvastatin Calcium
- Sacubitril Sodium
- Sacubitril Valsartan Trisodium (Amorphous)
- Sitagliptin Phosphate Anhydrous
- Sugammadex Sodium
- Succinylcholine Chloride
- Telmisartan
- Ticagrelor
- Ursodeoxycholic Acid
- Valsartan Disodium
R&D
Mankind Company boasts a dedicated Research and Development (R&D) center with three units strategically positioned in IMT Manesar, Gurugram, Haryana, and one in Mumbai, exclusively focusing on inhalation products in Thane, Maharashtra.
Notably, one unit within this R&D center holds recognition from the DSIR, while another unit complies with WHO GMP standards, having undergone rigorous inspection by the USFDA. Additionally, Mankind company operates two more R&D centers through non-wholly owned subsidiaries: the COPMED Research Centre in Dehradun, Uttarakhand, and the Mediforce Research Centre at Paonta Sahib, Himachal Pradesh.
As of December 2023, the company has successfully submitted 59 Abbreviated New Drug Applications (ANDAs) to the USFDA, encompassing ten Paragraph IV filings. Impressively, 37 of these have gained approval, extending to markets worldwide. The company has filed a total of 679 drug product applications, securing approvals for 491, with an additional 188 applications currently under meticulous review across various jurisdictions.
Furthermore, Mankind Pharma has submitted 25 Active Pharmaceutical Ingredient (API) Drug Master Files (DMFs) to the USFDA, receiving “Adequate letters” for 11, while the remaining are in the review pipeline. The company has also submitted 11 API Certificate of Suitability (CEPs) in Europe, achieving approvals for 10. Additionally, the Pharma has filed 3 DMFs in Australia and Malaysia, 2 in Canada and China, and one each in the UK and Korea.
Formulation Research and Development
Mankind company is equipped with in-house capabilities to spearhead the development of intricate generics spanning a diverse array of dosage forms. This includes the expertise to handle complex parenterals, ophthalmic solutions, suspensions, and gels. Notably, on July 29, 2022, Mankind company submitted an Investigational New Drug Application (INDA) for an innovative anti-diabetic NCE molecule, currently progressing through Phase I clinical trials.
As of December 31, 2022, the company is actively engaged in the pre-clinical development of two NCE molecules targeting autoimmune diseases and non-alcoholic steatohepatitis.
Mankind company is dedicated to advancing novel drug delivery systems, particularly focusing on inhalation solutions and pulmonary drug delivery. This encompasses the development of cutting-edge formulations such as dry powder inhalers, metered-dose inhalers, and oral films.
In addition, the company is committed to fortifying its capabilities across diverse product portfolios, including NCEs and Paragraph IV products. Furthermore, Mankind Pharma’s biotechnology team is currently immersed in the development of several biosimilars, including monoclonal antibodies, with a specific focus on anti-allergic and anti-cancer treatments.
The company’s commitment to innovation and diverse therapeutic areas underscores its dedication to delivering groundbreaking solutions in the pharmaceutical landscape.
- Phone Number +91 11 46541111
- Website Visit Website
- Products
- APIs
Amitriptyline HCl
Etoricoxib EU Process
Moxifloxacin HCl
Nitrofurantoin Macrocrystal
Nitrofurantoin Monohydrate
Ranolazine
Sugammadex Sodium
Clomipramine HCl
Haloperidol Base
Haloperidol Deconate - Contact Details